Left Atrial Appendage Closure Device
The role of LAA Closure devices for stroke risk reduction in patients with non valvular Atrial Fibrillation (AF)
- Dr. Ted Feldman -
“There are many patients who cannot take a full dose of NOACs. Today, we can apply the data that we have on WATCHMAN™ to all of these patients.
Which patient would benefit from LAAC Therapy? Hear It From The Experts
Prof. John Camm
Interview with Prof John Camm and Dr Tim Betts
Interview with Prof John Camm and Dr Shepal Doshi
Dr. Shepal Doshi explains how he discusses the WATCHMAN LAAC therapy with patients
EuroPCR 2015 Symposia
Chairperson: Alec VAHANIAN
Co-chairperson: Maurice BUCHBINDER
Speakers: Maurice BUCHBINDER, Martin W. BERGMANN, Ignacio CRUZ-GONZALEZ, Horst SIEVERT, Alec VAHANIAN
This content is meant for educational purposes only. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Information for the use only in countries with applicable health authority product registrations. This material is not intended for use or distribution in France.